Key stats
About CHINA ASSET MANAGEMENT (HK) CHINAAMC HANG SENG BIOTECH ETF HKD
Home page
Inception date
Mar 18, 2021
Replication method
Physical
Dividend treatment
Distributes
Primary advisor
China Asset Management (Hong Kong) Ltd.
ISIN
HK0000711199
The investment objective of the Sub-Fund is to provide investment results that, before fees and expenses, closely correspond to the performance of the Hang Seng Hong Kong-Listed Biotech Index.
Classification
Returns
1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
---|---|---|---|---|---|---|
Price performance | — | — | — | — | — | — |
NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.78%
Health Technology86.96%
Consumer Non-Durables3.95%
Retail Trade2.19%
Technology Services1.97%
Health Services1.81%
Distribution Services1.45%
Commercial Services1.44%
Bonds, Cash & Other0.22%
Cash0.22%
Stock breakdown by region
Asia90.28%
North America9.72%
Latin America0.00%
Europe0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history